title: [Omega-3 fatty acids as an option in the treatment of NAFLD].
abstract: BACKGROUND
  Human tissues or organs vary in the content of long-chain omega-3 fatty acids, in case of diseases the content may even change. These findings cannot be extrapolated from blood lipids.
  
  
  METHODS
  Overview
  
  
  RESULTS
  By means of liver biopsies it has been shown that eicosapentaenoic acid (EPA) significantly decreases with raising triglyceride accumulation in hepatocytes. This is associated with increased histological signs of inflammation in liver parenchyma. In a study the intake of omega-3 fatty acids (1 g/d) resulted in a rising percentage of EPA in liver triglycerides associated with a reduction of liver fat and inflammation markers.
  
  
  CONCLUSIONS
  From the results a hitherto widely ignored indication for NAFLD with or without metabolic syndrome can be derived.
authors.affiliation: Mitglied der ISSFAL (International Society for the Study of Fatty Acids and Lipids), der DAEM (Deutsche Akademie for Ernihrungsmedizin) und des Wissenschaftlichen Beirats im Arbeitskreis Omega-3 e.V., Berlin.
authors.forename: P
authors.initials: P
authors.lastname: Singer
mesh_terms: D001706:Biopsy; D015525:Fatty Acids, Omega-3 / Q000378:metabolism / Q000627:therapeutic use*; D005234:Fatty Liver / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008066:Lipolysis / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000473:pathology; D065626:Non-alcoholic Fatty Liver Disease; D014280:Triglycerides / Q000378:metabolism
chemical_list: D015525:Fatty Acids, Omega-3; D014280:Triglycerides